Fundraising Fox
Dyne Therapeutics
NASDAQ: DYNUnicorn · $1.4BWaltham, US · Founded 2017 · Delaware corporation · 316 employees on LinkedIn · 7 known investors
Find your way into Dyne Therapeutics
Sign up to see every warm intro you have to Dyne Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dyne Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company focuses on discovery, clinical development, and commercialization of treatments for rare genetic disorders.
Founders & leadership
Dyne Therapeutics was founded in 2017 by Romesh Subramanian, Ph.D..
Board
Investors · 7
How we know: Atlas Venture's portfolio page · the S-1 prospectus · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: MPM BioImpact's portfolio page · Not right? Tell us
How we know: Vida Ventures's portfolio page · the S-1 prospectus · the VCSheet dataset · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Funding
SEC filings, press & company announcements$115.7M disclosed across 1 of 2 rounds · 2019–2020
- Undisclosed amountSeries AApr 2019Source ↗
▶$115.7MraisedAug 2020 · 19 investors · BiotechnologyRule 506(b)
- Lawrence Klein, Ph.D.Director
- Richard ScalzoExecutive Officer
- Joshua BrummExecutive Officer, Director
- David LubnerDirector
- Edward HurwitzDirector
- Dirk KerstenDirector
- Jonathan McNeill, M.D.Executive Officer
- Catherine Stehman-Breen, M.D.Director
- Jason RhodesDirector
- Oxana Beskrovnaya, Ph.D.Executive Officer
- Romesh Subramanian, Ph.D.Executive Officer
- Offering amount
- $115.7M
- Amount sold
- $115.7M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
The Dyne Therapeutics mafia →6 people who came through Dyne Therapeutics went on to found or lead other companies.
Related companies · 5
Companies working in the same space as Dyne Therapeutics.
Frequently asked questions
- What does Dyne Therapeutics do?
- Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company focuses on discovery, clinical development, and commercialization of treatments for rare genetic disorders.
- Who founded Dyne Therapeutics?
- Dyne Therapeutics was founded by Romesh Subramanian, Ph.D. in 2017.
- Who are Dyne Therapeutics's investors?
- Dyne Therapeutics's investors include Atlas Venture, MPM BioImpact, Vida Ventures, Wellington Management, Forbion, Hercules Capital, Inc., RA Capital.
- How much funding has Dyne Therapeutics raised?
- Dyne Therapeutics has disclosed $115.7M raised across 1 of its 2 known rounds.
- Where is Dyne Therapeutics headquartered?
- Dyne Therapeutics is headquartered in Waltham, US.